Tune & Track
Affinity Tuned CAR T Cells for Solid Tumors

Unlocking the Full Potential of CAR T Cell Therapies

AffyImmune is harnessing the power of the body’s own immune system to seek and destroy cancer cells by overcoming the immunotherapy challenges for solid tumors. AffyImmune’s proprietary “Tune & Track” technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues.

Science

Our core focus is on fine-tuning the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells to prevent toxicity and ensuring more natural, robust, and long-lasting activity of the CAR T cells. We engineer our CAR T cells to be monitorable in real-time in patients during treatment.

Discover More

Leadership

The leadership team combines a depth of experience in biotechnology drug development with a passion for creating new, patient-centric, life-saving treatments.

Get to Know Us

Pipeline

Our “Tune & Track” technology is currently being applied to multiple target antigens for the treatment of various solid tumors.

View Pipeline

FEATURED NEWS

FEATURED JOBS

Associate Director/Director of Clinical Biomarkers and CDx

AffyImmune Therapeutics (“Affy”), a clinical stage biotechnology company focused on creating technologies that expand the utility and improve the safety of cell-based immunotherapy for cancer, is seeking an Associate Director, Clinical Biomarkers and CDx (Director, depending on experience) to develop and commercialize companion diagnostic [...]